Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer

  • Technology appraisal guidance
  • TA347
  • Published: 

History

Final draft guidance

Draft guidance

Lung cancer (non-small cell) - nintedanib: equality impact assessment - guidance development

Lung cancer (non-small cell) - nintedanib: equality impact assessment - scoping

Lung cancer - nintedanib: final scope

Lung cancer - nintedanib: final matrix

Lung cancer - nintedanib: response to consultee and commentator comments on the draft scope and provisional matrix

Lung cancer - nintedanib: draft scope for consultation (pre-referral) - August 2013

Lung cancer - nintedanib: provisional matrix (pre-referral) - August 2013